Is DRRX or QYLD a better dividend investment in 2026?

DRRX currently yields 104.71% with a 5% 5-year dividend growth rate. QYLD yields 12.24% with -2.1% growth. The better choice depends on your goal: DRRX offers higher current income.

What is the dividend yield difference between DRRX and QYLD?

DRRX has a forward dividend yield of 104.71% ($2.00/share annually). QYLD yields 12.24% ($2.04/share annually). The yield gap is 92.47 percentage points.

Home › Compare › DRRX vs QYLD

DRRX vs QYLD: Dividend Comparison 2026

DRRX yields 104.71% · QYLD yields 12.24%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 DRRX wins by $4.69M in total portfolio value

INVESTMENT

TIME HORIZON10 years

DRRX

● Live price

104.71%

Share price

$1.91

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.71M

Annual income

$1,637,812.78

Full DRRX calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

12.24%

Share price

$16.70

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$26.5K

Annual income

$6,038.84

Full QYLD calculator →

Portfolio growth — DRRX vs QYLD

📍 DRRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	DRRX	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, DRRX + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

DRRX pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DRRX

Annual income on $10K today (after 15% tax)

$8,900.52/yr

After 10yr DRIP, annual income (after tax)

$1,392,140.86/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,040.82/yr

After 10yr DRIP, annual income (after tax)

$5,133.01/yr

At 15% tax rate, DRRX beats the other by $1,387,007.85/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DRRX + QYLD for your $10,000?

DRRX: 50%QYLD: 50%

100% QYLD50/50100% DRRX

Portfolio after 10yr

$2.37M

Annual income

$821,925.81/yr

Blended yield

34.67%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on DRRX right now

DRRX

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-67.3

Piotroski

2/9

QYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DRRX buys

QYLD buys

No recent congressional trades found for DRRX or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricDRRXQYLD

Forward yield	104.71% ✓	12.24%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.71M	$26.5K ✓
Annual income after 10y	$1,637,812.78 ✓	$6,038.84
Total dividends collected	$4.23M	$28.5K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: DRRX vs QYLD ($10,000, DRIP)

Year	DRRX Portfolio	DRRX Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$21,171	$10,471.20	$10,384	$1,224.49	+$10.8K → DRRX
2	$43,372	$20,718.50	$10,900	$1,388.18	+$32.5K → DRRX
3	$86,075	$39,667.56	$11,576	$1,590.76	+$74.5K → DRRX
4	$165,674	$73,573.88	$12,447	$1,844.20	+$153.2K → DRRX
5	$309,620	$132,347.88	$13,567	$2,164.97	+$296.1K → DRRX
6	$562,449	$231,156.47	$15,003	$2,576.05	+$547.4K → DRRX
7	$994,265	$392,443.71	$16,853	$3,110.04	+$977.4K → DRRX
8	$1,712,217	$648,353.89	$19,251	$3,813.85	+$1.69M → DRRX
9	$2,875,555	$1,043,482.55	$22,390	$4,756.08	+$2.85M → DRRX
10	$4,714,656	$1,637,812.78	$26,548	$6,038.84	+$4.69M → DRRX

DRRX vs QYLD: Complete Analysis 2026

DRRX — Stock

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Full DRRX Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this DRRX vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DRRX vs SCHD DRRX vs JEPI DRRX vs O DRRX vs KO DRRX vs MAIN DRRX vs XYLD DRRX vs JEPQ DRRX vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.